BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» Arbitrator Awards Amgen $150M In Johnson & Johnson Dispute
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Arbitrator Awards Amgen $150M In Johnson & Johnson Dispute
Oct. 22, 2002
By
Randy Osborne
No Comments
Amgen Inc.'s arbitration against Johnson & Johnson over epoetin alfa ended with a bang - the pharmaceutical company must pay Amgen $150 million - but who (if anyone) should whimper was uncertain, since Amgen had asked for much more. (BioWorld Today)
BioWorld